Dividends Inside 
Abbott Laboratories
ABT
$95.40 (+ $3.22 + 3.49%)
Last updated: 2026-07-04 03:50 UTC
Abbott Laboratories trades under ticker ABT on NYSE as a stock. Use this page to review stock price, dividends, and price history. The page also shows Healthcare exposure. Identifiers: ISIN US0028241000, CUSIP 002824100.
About the Company
Abbott Laboratories is a diversified healthcare company that discovers, develops, manufactures, and sells a comprehensive range of medical products and pharmaceuticals globally. The company operates through four primary segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Its medical device portfolio includes pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, and catheters designed to treat cardiovascular and neurological conditions. Abbott also produces continuous glucose monitors for diabetes management and diagnostic equipment including immunoassays and point-of-care testing kits. In nutrition, the company manufactures infant formula, adult nutritional liquids, and specialized dietary products for pediatric and adult populations. Abbott's established pharmaceutical segment offers branded generic medications across multiple therapeutic areas. With headquarters in Abbott Park, Illinois, and operations spanning more than 160 countries, Abbott derives approximately 60 percent of its sales from international markets, making it a truly global healthcare provider serving healthcare professionals, patients, and consumers worldwide.
Price History
Latest News for ABT
10 Quality Stocks That Hit New Lows This Week—and Look Like Bargains
Even as tech surges, many other sectors in the market are trading at surprisingly attractive prices.
Even a High-Priced Market Has Bargains. 10 Undervalued Blue-Chip Stocks.
Even as tech surges, many other sectors in the market are trading at surprisingly attractive prices.
Jim Cramer Compares the Current Selloff in Abbott Labs to the 1999 Market Environment
Abbott Laboratories (NYSE:ABT) was one of the stocks on which Jim Cramer shared his take, explaining that dot-com analogies do not hold up in this market. Cramer highlighted it as one of the “greatest American companies,” as he said: …Let’s talk about some similarities that have now been popping up, okay? In 1999, we saw […]
How The Investment Narrative For Abbott Laboratories (ABT) Is Shifting With Recent Analyst Resets
Abbott Laboratories is under fresh scrutiny as price targets are reset, with some analysts trimming their expectations and others keeping fair value estimates such as US$118.64 broadly intact. The more cautious tone in recent research, including cuts to targets and removal from a key US conviction list, sits alongside ongoing supportive views that still see room for upside versus analysts’ own fair value work. As you read on, you will see how to track these shifting targets and use the...
Should You Buy, Hold or Sell BSX Stock Amid Cardiovascular Boom?
Boston Scientific rides on cardiovascular device growth with FARAPULSE and WATCHMAN momentum, but margin pressure and weaker estimates cloud the outlook.
Australia Regenerative Medicine Market Research Trends and Forecasts Report 2026-2035 Featuring Prominent Players Such as Abbott Laboratories, Astellas Pharma, and Roche
The Australia regenerative medicine market offers significant opportunities in cellular therapies, tissue engineering, and aesthetic applications, driven by aging populations and chronic disease prevalence. Key growth is seen in oncological applications and hospital adoption, with strong government backing and technological advancements enhancing potential.Dublin, May 13, 2026 (GLOBE NEWSWIRE) -- The "Australia Regenerative Medicine Market - Distribution by Type of Products, Type of Therapeutic